非TNFi生物制剂与靶向合成DMARDs在类风湿关节炎相关间质性肺病中的比较:倾向评分匹配、活性对照、新使用者研究
本研究采用目标试验模拟框架,在2006至2020年美国退伍军人事务部数据中,将启动阿巴西普、托珠单抗或托法替布的患者与启动利妥昔单抗者按1:1倾向评分匹配,比较类风湿关节炎相关间质性肺病患者的死亡与呼吸相关住院复合结局。三年随访中各组主要复合结局无显著差异,但估计值不精确且可能存在残余混杂。
要点
- 阿巴西普、托珠单抗、托法替布与利妥昔单抗相比,主要复合结局均无显著差异。
- 作者认为估计值不精确且可能存在残余混杂,强调需在RA-ILD中开展先进免疫调节疗法的临床试验。
核心结论
- 在启动不同非TNFi生物制剂或靶向合成DMARDs的RA-ILD患者中,未发现死亡率或呼吸相关住院存在显著差异,但估计值不精确且可能存在残余混杂。
研究设计与样本
- 采用目标试验模拟框架,模拟三项试验,分别比较阿巴西普、托珠单抗和托法替布与利妥昔单抗(参照组)。
- 使用2006至2020年美国退伍军人事务部(VA)全国数据,将符合经验证的RA-ILD算法的非TNFi b/tsDMARDs启动者按1:1进行倾向评分匹配。
- 倾向评分模型包括人口学特征、合并症、总体健康状况指标及多项RA和ILD相关严重程度指标。
- 主要随访期为三年,次要随访期为一年,复合结局为死亡和呼吸相关住院,通过VA数据及与全国死亡指数和Medicare的链接确认。
- 采用Cox回归模型分析结局并校正任何不平衡变量,并进行多项敏感性和亚组分析。
主要发现
- 主要队列中,阿巴西普(n=150)、托珠单抗(n=73)和托法替布(n=94)分别与等量利妥昔单抗启动者1:1匹配(平均年龄68.1-69.4岁,男性占88-92%)。
- 次要分析、亚组分析和敏感性分析支持主要发现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 估计值不精确。
- 可能存在残余混杂。
- 作者强调需要在RA-ILD中开展先进免疫调节疗法的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to compare treatment outcomes in rheumatoid arthritis-associated interstitial lung disease (RA-ILD) between initiators of rituximab, abatacept, tocilizumab, and tofacitinib using the Target Trial Emulation Framework. METHODS: We emulated three trials comparing abatacept, tocilizumab, and tofacitinib with rituximab (reference). Patients fulfilling validated RA-ILD algorithms initiating one of these non-TNFi b/tsDMARDs were propensity score (PS)-matched (1:1) using national Veterans Affairs (VA) data from 2006 to 2020. PS models included demographics, comorbidities, general health status indicators, and several RA- and ILD-related severity measures. Composite study outcomes were death and respiratory-related hospitalization, ascertained by VA data and linkages to the National Death Index and Medicare, over three-year (primary) and one-year follow-up periods (secondary). Cox regression models were used to analyze study outcomes adjusting for any unbalanced variables. Several sensitivity and subgroup analyses were performed. RESULTS: In the primary cohort, we 1:1 matched abatacept (n = 150), tocilizumab (n = 73), and tofacitinib (n = 94) with equal numbers of rituximab initiators (mean age 68.1-69.4 years, 88-92 % male). There were no significant differences in the primary composite outcome among any of the comparisons (abatacept aHR: 1.03 [0.72, 1.47]; tocilizumab aHR: 1.15 [0.68, 1.93]; tofacitinib aHR: 0.89 [0.54, 1.46]). Secondary, subgroup, and sensitivity analyses supported the main findings. CONCLUSIONS: We did not find significant differences in mortality or respiratory hospitalization between RA-ILD patients initiating different non-TNFi b/tsDMARDs, though estimates were imprecise, and residual confounding may be present. These findings emphasize the need for clinical trials of advanced immunomodulatory therapies in RA-ILD.
引用
- Frideres H, Wichman CS, Dong J, et al. Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user study. Semin Arthritis Rheum. 2025. PMID: 40280051. doi:10.1016/j.semarthrit.2025.152735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。